6-formyl-2-trifluoromethyl-2H-chromene-3-carboxylic acid | 215122-80-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 6-formyl-2-trifluoromethyl-2H-chromene-3-carboxylic acid
• 英文别名: 6-Formyl-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid；6-formyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid
• CAS: 215122-80-8
• 化学式: C₁₂H₇F₃O₄
• 分子量: 272.18
• InChiKey: DEIAIXWIMOETNX-UHFFFAOYSA-N

物化性质

• 沸点：
  388.4±42.0 °C(Predicted)
• 密度：
  1.550±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  6-formyl-2-trifluoromethyl-2H-chromene-3-carboxylic acid 在 溶剂黄146 作用下， 以 四氢呋喃 、 sodium tetrahydroborate 、 乙醇 为溶剂， 以31%的产率得到6-hydroxymethyl-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid
  参考文献：
  名称：

  Substituted benzopyran analogs for the treatment of inflammation

  摘要：

  描述了一类苯并吡喃、苯并硫吡喃、二氢喹啉、二氢萘和其类似物，用于治疗环氧化酶-2介导的疾病。特别感兴趣的化合物由Formula I'定义，其中X、A.sup.1、A.sup.2、A.sup.3、A.sup.4、R、R"、R.sup.1和R.sup.2如规范中所述。

  公开号：

  US06077850A1
• 作为产物：
  描述：

  ethyl 6-formyl-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylate 在 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 6-formyl-2-trifluoromethyl-2H-chromene-3-carboxylic acid
  参考文献：
  名称：

  The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates

  摘要：

  In this manuscript, we report the discovery of the substituted 2-trifluoromethyl-2H-benzopyran-3-carboxylic acids as a novel series of potent and selective cyclooxygenase-2 (COX-2) inhibitors. We provide the structure-activity relationships, optimization of design, testing criteria, and human half-life data. The challenge of a surprisingly long half-life (t(1/2) = 360 h) of the first clinical candidate 1 and human t(1/2) had been difficult to predict based on allometric scaling for this class of highly ppb compounds. We used a microdose strategy which led to the discovery of clinical agents 18c-(S), 29b-(S), and 34b-(S) with human half-life of 57, 13, and 11 h. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.059

文献信息

• Substituted benzopyran derivatives for the treatment of inflammation
  申请人：G.D. Searle & Co.

  公开号：US06034256A1

  公开（公告）日：2000-03-07

  A class of benzopyran, derivatives is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I' ##STR1## wherein X, A.sup.1, A.sup.2, A.sup.3, A.sup.4, R, R", R.sup.1 and R.sup.2 are as described in the specification.

  所描述的苯并吡喃类衍生物用于治疗环氧合酶-2介导的疾病。特别感兴趣的化合物由式I'定义，其中X、A.sup.1、A.sup.2、A.sup.3、A.sup.4、R、R"、R.sup.1和R.sup.2如规范中描述。
• Antiangiogenic combination therapy for the treatment of cancer
  申请人：——

  公开号：US20020103141A1

  公开（公告）日：2002-08-01

  The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective COX-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.

  本发明提供了一种DNA拓扑异构酶I抑制剂和选择性COX-2抑制剂的组合物，用于预防、治疗和/或减少哺乳动物发生肿瘤性疾病的风险。
• Piperidine-based heterocyclic oxalyl amides as potent p38α MAP kinase inhibitors
  作者：Babu J. Mavunkel、John J. Perumattam、Xuefei Tan、Gregory R. Luedtke、Qing Lu、Don Lim、Darin Kizer、Sundeep Dugar、Sarvajit Chakravarty、Yong-jin Xu、Joon Jung、Albert Liclican、Daniel E. Levy、Jocelyn Tabora

  DOI：10.1016/j.bmcl.2009.12.031

  日期：2010.2

  The design and synthesis of a new class of p38α MAP kinase inhibitors based on 4-fluorobenzylpiperidine heterocyclic oxalyl amides are described. Many of these compounds showed low-nanomolar activities in p38α enzymatic and cell-based cytokine TNFα production inhibition assays. The optimal linkers between the piperidine and the oxalyl amide were found to be [6,5] fused ring heterocycles. Substituted

  描述了基于4-氟苄基哌啶杂环草酰酰胺的新型p38αMAP激酶抑制剂的设计与合成。这些化合物中的许多在p38α酶促和基于细胞的细胞因子TNFα产生抑制试验中均显示出低纳摩尔活性。发现哌啶和草酰酰胺之间的最佳连接基是[6,5]稠环杂环。在细胞测定中，取代的吲哚和氮杂吲哚是优选的结构基序。
• Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
  申请人：Pulaski P. Steven

  公开号：US20050014729A1

  公开（公告）日：2005-01-20

  A method for preventing or treating dermatological disorders and dermatological disorder-related complications in a subject involves a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a dermatological treatment agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and a dermatological treatment agent. Pharmaceutical compositions and kits for implementing the present method are also described.

  一种预防或治疗受试者的皮肤病和与皮肤病相关并发症的方法涉及使用Cox-2抑制剂进行单独治疗或与Cox-2抑制剂和皮肤治疗剂的联合治疗。还描述了包含Cox-2抑制剂和皮肤治疗剂的治疗组合物。还描述了用于实施本方法的药物组合物和工具包。
• [EN] METHOD FOR PREVENTING OR TREATING AN OPTIC NEUROPATHY<br/>[FR] METHODE PERMETTANT DE PREVENIR OU DE TRAITER UNE NEUROPATHIE OPTIQUE
  申请人：PHARMACIA CORP

  公开号：WO2005021004A1

  公开（公告）日：2005-03-10

  The present invention provides methods and compositions for the prevention and/or treatment of an optic neuropathy, comprising a Cox-2 inhibitor and an intraocular pressure reducing agent.

  本发明提供了一种预防和/或治疗视神经病变的方法和组合物，包括Cox-2抑制剂和降低眼压的药剂。